Hims & Hers Health (HIMS) – Research Analysts’ Weekly Ratings Updates

Hims & Hers Health (NYSE: HIMS) recently received a number of ratings updates from brokerages and research firms:

• 5/22/2025 – Hims & Hers Health was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 5/7/2025 – Hims & Hers Health had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
• 5/6/2025 – Hims & Hers Health had its “mixed” rating reaffirmed by analysts at UBS Group AG.
• 5/6/2025 – Hims & Hers Health had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $39.00 price target on the stock, up previously from $35.00.
• 5/6/2025 – Hims & Hers Health had its “sell” rating reaffirmed by analysts at Citigroup Inc.. They now have a $30.00 price target on the stock, up previously from $25.00.
• 5/6/2025 – Hims & Hers Health had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $61.00 price target on the stock.
• 4/29/2025 – Hims & Hers Health had its price target raised by analysts at Bank of America Co. from $22.00 to $26.00. They now have an “underperform” rating on the stock.
• 4/29/2025 – Hims & Hers Health was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating. They now have a $30.00 price target on the stock, down previously from $44.00.
• 4/29/2025 – Hims & Hers Health had its price target lowered by analysts at Morgan Stanley from $60.00 to $40.00. They now have an “equal weight” rating on the stock.
• 4/25/2025 – Hims & Hers Health had its price target lowered by analysts at Citigroup Inc. from $27.00 to $25.00. They now have a “sell” rating on the stock.
• 4/10/2025 – Hims & Hers Health had its price target lowered by analysts at Truist Financial Co. from $39.00 to $33.00. They now have a “hold” rating on the stock.
• 4/2/2025 – Hims & Hers Health had its “sell” rating reaffirmed by analysts at Citigroup Inc..

Hims & Hers Health Trading Up 2.6%

HIMS opened at $54.89 on Monday. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The firm has a market capitalization of $12.29 billion, a PE ratio of 124.75 and a beta of 1.84. The firm’s 50-day moving average price is $37.95 and its 200 day moving average price is $35.16.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business’s revenue was up 110.7% on a year-over-year basis. During the same period last year, the company posted $0.05 EPS. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 23,287 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total transaction of $798,976.97. Following the completion of the sale, the insider now directly owns 209,661 shares of the company’s stock, valued at approximately $7,193,468.91. This trade represents a 10.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $58.40, for a total transaction of $7,482,616.80. Following the completion of the transaction, the chief executive officer now directly owns 89,311 shares in the company, valued at $5,215,762.40. The trade was a 58.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 601,633 shares of company stock worth $24,349,726 in the last quarter. Company insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the first quarter worth about $30,000. Crewe Advisors LLC purchased a new stake in Hims & Hers Health during the 4th quarter worth approximately $28,000. Blume Capital Management Inc. lifted its holdings in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares in the last quarter. UMB Bank n.a. boosted its position in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after buying an additional 933 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Hims & Hers Health in the 1st quarter valued at approximately $41,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.